Literature DB >> 17220876

Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression.

Yisong Y Wan1, Richard A Flavell.   

Abstract

The naturally occurring regulatory T cell (T(r)) is the pivotal cell type that maintains self-tolerance and exerts active immune suppression. The development and function of T(r) cells is controlled by Foxp3 (refs 1, 2), a lack of which results in loss of T(r) cells and massive multi-organ autoimmunity in scurfy mice and IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) patients. It is generally thought that, through a binary mechanism, Foxp3 expression serves as an on-and-off switch to regulate positively the physiology of T(r) cells; however, emerging evidence associates decreased Foxp3 expression in T(r) cells with various immune disorders. We hypothesized that Foxp3 regulates T(r) cell development and function in a dose-dependent, non-binary manner, and that decreased Foxp3 expression can cause immune disease. Here, by generating a mouse model in which endogenous Foxp3 gene expression is attenuated in T(r) cells, we show that decreased Foxp3 expression results in the development of an aggressive autoimmune syndrome similar to that of scurfy mice, but does not affect thymic development, homeostatic expansion/maintenance or transforming-growth-factor-beta-induced de novo generation of Foxp3-expressing cells. The immune-suppressive activities of T cells with attenuated Foxp3 expression were nearly abolished in vitro and in vivo, whereas their anergic properties in vitro were maintained. This was accompanied by decreased expression of T(r) cell 'signature genes'. Notably, T cells expressing decreased Foxp3 preferentially became T-helper 2 (T(h)2)-type effectors even in a T(h)1-polarizing environment. These cells instructed T(h)2 differentiation of conventional T cells, which contributed to the immune diseases observed in these mice. Thus, decreased Foxp3 expression causes immune disease by subverting the suppressive function of T(r) cells and converting T(r) cells into effector cells; these findings are important for understanding the regulation of T(r) cell function and the aetiology of various human immune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220876     DOI: 10.1038/nature05479

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  375 in total

1.  Cellular therapies supplement: the role of granulocyte macrophage colony-stimulating factor and dendritic cells in regulatory T-cell homeostasis and expansion.

Authors:  Tao Zou; Atsushi Satake; Priti Ojha; Taku Kambayashi
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

Review 2.  Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?

Authors:  Qin Lan; Huimin Fan; Valerie Quesniaux; Bernhard Ryffel; Zhongmin Liu; Song Guo Zheng
Journal:  J Mol Cell Biol       Date:  2011-11-22       Impact factor: 6.216

3.  Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells.

Authors:  Xuguang Tai; François Van Laethem; Leonid Pobezinsky; Terry Guinter; Susan O Sharrow; Anthony Adams; Larry Granger; Michael Kruhlak; Tullia Lindsten; Craig B Thompson; Lionel Feigenbaum; Alfred Singer
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 4.  Molecular and functional heterogeneity of T regulatory cells.

Authors:  Lequn Li; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2011-08-30       Impact factor: 3.969

Review 5.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

Review 6.  An update on regulatory T cells in transplant tolerance and rejection.

Authors:  Xian Chang Li; Laurence A Turka
Journal:  Nat Rev Nephrol       Date:  2010-08-03       Impact factor: 28.314

Review 7.  Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6.

Authors:  Svetlana Chapoval; Preeta Dasgupta; Nicolas J Dorsey; Achsah D Keegan
Journal:  J Leukoc Biol       Date:  2010-03-24       Impact factor: 4.962

Review 8.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

9.  The role of the CD58 locus in multiple sclerosis.

Authors:  Philip L De Jager; Clare Baecher-Allan; Lisa M Maier; Ariel T Arthur; Linda Ottoboni; Lisa Barcellos; Jacob L McCauley; Stephen Sawcer; An Goris; Janna Saarela; Roman Yelensky; Alkes Price; Virpi Leppa; Nick Patterson; Paul I W de Bakker; Dong Tran; Cristin Aubin; Susan Pobywajlo; Elizabeth Rossin; Xinli Hu; Charles W Ashley; Edwin Choy; John D Rioux; Margaret A Pericak-Vance; Adrian Ivinson; David R Booth; Graeme J Stewart; Aarno Palotie; Leena Peltonen; Bénédicte Dubois; Jonathan L Haines; Howard L Weiner; Alastair Compston; Stephen L Hauser; Mark J Daly; David Reich; Jorge R Oksenberg; David A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 10.  The plasticity of human Treg and Th17 cells and its role in autoimmunity.

Authors:  Markus Kleinewietfeld; David A Hafler
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.